Viridian Therapeutics
VRDN
18.28
+0.06
+0.33%
Viridian Therapeutics
US · VRDN
#2731 by market cap
Listed 1970
18.28
+0.06
+0.33%
Live - 5344 symbols - heartbeat 28s ago
· 2026-10-07 21:23
After-hours
18.22
-0.33%
Overnight
18.07
-1.15%
- Market cap
- 2.07B
- P/E (TTM)i
- -5.38
- P/Bi
- 3.67
- EPSi
- -3.32
- Div yieldi
- 0.00%
- 52W posi
- 24%
Reader sentiment
Are you bullish or bearish on VRDN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- Total institutional ownership rose 2.5 percentage points.
Institutional ownership
- Held by institutions
- 119.61% +2.45pp
- Institutions
- 266
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund71.93%
Hedge Fund32.86%
VC/PE Fund8.77%
Public Company2.83%
Private Company1.45%
Sovereign Wealth Fund1.32%
Government Pension Fund0.31%
Insurance Company0.11%
Top holders as of 2026-06-30
FMR
14.66% · 16.60M sh
BlackRock
7.55% · 8.55M sh
Bellevue Asset Management AG
5.94% · 6.73M sh
Paradigm Biocapital Advisors LP
5.93% · 6.72M sh
State Street Global Advisors
5.41% · 6.12M sh
T. Rowe Price Group, Inc.
5.07% · 5.75M sh
Point72 Asset Management, L.P.
5.02% · 5.69M sh
Vanguard Capital Management, LLC
4.62% · 5.23M sh
Fairmount Funds Management LLC
4.49% · 5.09M sh
Deep Track Capital, LP
3.17% · 3.59M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 11 sells
| Name | Role | Stake |
|---|---|---|
| Radhika Tripuraneni | Chief Medical Officer | 0.04% |
| Stephen Mahoney | Chief Executive Officer | 0.03% |
| Thomas Beetham | Chief Operating Officer | 0.01% |
| Seth Harmon | Senior VP of Finance and Accounting, Principal Financial & Accounting Officer | 0.01% |
| Arlene Morris | Independent Director | -- |
| Jeffrey Ajer | Director | -- |
| Tomas Kiselak | Independent Chairperson of Board | -- |
| Christopher Cain | Director | -- |
| Jennifer Moses | Independent Director | -- |
| Fairmount Funds Management LLC | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-18 | Jennifer Tousignant | Chief Legal Officer | Open Market Disposition | -4,212 | $24.50 |
| 2026-08-18 | Jennifer Tousignant | Chief Legal Officer | Derivative Exercise and Sale | -10,000 | $14.41–24.50 |
| 2026-08-13 | Radhika Tripuraneni | Chief Medical Officer | Derivative Exercise and Retained | +40,000 | $13.21 |
| 2026-06-30 | Arlene Morris | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Jeffrey Ajer | Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Tomas Kiselak | Independent Chairperson of Board | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Christopher Cain | Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Jennifer Moses | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Sarah Gheuens | Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-05-10 | Fairmount Funds Management LLC | -- | Open Market Acquisition | +1,176,470 | $17.00 |
| 2026-03-03 | Thomas Beetham | Chief Operating Officer | Intent to Sell (Form 144) | -3,048 | $30.19 |
| 2026-03-03 | Stephen Mahoney | Chief Executive Officer | Intent to Sell (Form 144) | -7,408 | $30.19 |
| 2026-03-03 | Seth Harmon | Senior VP of Finance and Accounting, Principal Financial & Accounting Officer | Intent to Sell (Form 144) | -2,031 | $30.19 |
| 2026-03-03 | Jennifer Tousignant | Chief Legal Officer | Intent to Sell (Form 144) | -1,675 | $30.19 |
| 2026-03-02 | Thomas Beetham | Chief Operating Officer | Sale to Issuer | -3,048 | $30.19 |
| 2026-03-02 | Thomas Beetham | Chief Operating Officer | Derivative Exercise and Retained | +9,409 | -- |
| 2026-03-02 | Stephen Mahoney | Chief Executive Officer | Sale to Issuer | -7,408 | $30.19 |
| 2026-03-02 | Stephen Mahoney | Chief Executive Officer | Derivative Exercise and Retained | +18,357 | -- |
| 2026-03-02 | Seth Harmon | Senior VP of Finance and Accounting, Principal Financial & Accounting Officer | Sale to Issuer | -2,031 | $30.19 |
| 2026-03-02 | Seth Harmon | Senior VP of Finance and Accounting, Principal Financial & Accounting Officer | Derivative Exercise and Retained | +6,267 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 21:23:26 · For reference only, not investment advice and not tailored to your situation.